Navigation Links
Efficacy and Safety Data from Phase 2B Trials of Janssen's Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
Date:11/10/2012

BOSTON, Nov. 10, 2012 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. (Janssen) today announced that the use of one once-daily pill of the investigational protease inhibitor simeprevir (TMC435) administered with pegylated interferon and ribavirin led to higher rates of sustained viral response at 24 weeks (SVR24) compared to placebo in patients with Metavir scores of F3 and F4 who were treatment naive and treatment experienced with genotype 1 hepatitis C. Simeprevir was also generally well tolerated and the overall incidence of serious adverse events (AEs) was similar across all treatment arms. The data from the Phase 2b PILLAR and ASPIRE trials were presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).

In treatment-naive patients with a Metavir score of F3 (PILLAR), the primary endpoint of SVR24 was achieved in 79 percent of patients in the simeprevir group compared to 72 percent in the control group (pegylated interferon and ribavirin alone). In treatment-experienced patients with a Metavir score of F3 (ASPIRE), SVR24 was achieved in 48 percent of patients in the simeprevir group compared to 8 percent in the control group. In treatment-experienced patients with a Metavir score of F4 (ASPIRE), SVR was achieved in 62 percent of patients in the simeprevir group compared to 0 percent in the control group. In both the PILLAR and ASPIRE trials, serious AEs occurred in 7.6 percent of patients receiving simeprevir plus pegylated interferon and ribavirin compared to 9.8 percent of patients receiving pegylated interferon and ribavirin alone.

"Hepatitis C patients with Metavir scores of F3 and F4 have advanced fibrosis of the liver and are harder to cure than those with limited fibrosis," said Fred Poordad, M.D., chief medical officer of Alamo Medical Research Center and investigator in the ASPIRE and PILLAR studies. "The results presented at AASLD suggest that simeprevir could represent an important new trea
'/>"/>

SOURCE Janssen Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. JAMA Study Demonstrates Efficacy of Life Technologies Lung Cancer Test in Detecting Early Metastases, Supports Screening for Lung Cancer
2. Optimization of Comparative Efficacy Trials
3. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
4. Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
5. MedQIA unique CAD algorithm for Quantitation of lung involvement in diffuse lung disease used as treatment efficacy end point in study to be reported at the ERS Annual Conference in Vienna, Austria: September 1-5, 2012
6. Renal Dialysis Equipment Market to 2017- Lower Costs and Similar Efficacy Rates as Hemodialysis to Increase Adoption Rates of Peritoneal Dialysis
7. FDAnews announces Fifth Annual Risk Management & Drug Safety Summit
8. Immunomic Therapeutics Begins Phase I Japanese Red Cedar JRC-LAMP-Vax Vaccine Safety Study
9. Arisaph Pharmaceuticals Reports Positive Results From Two Safety Clinical Trials For Its Niacin Analog (ARI-3037MO)
10. Compounding Pharmacy Safety: Dr. Paul Savage Published in IMJC Post #Meningitis Outbreak
11. Kansas Car Umbrella Encouraged By New Safety Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014 The Pharmaceutical Care Management ... managers (PBMs), today filed a lawsuit in ... Iowa law that restricts tools ... the state,s employers and consumers.  The ... severely restricting the use of Maximum Allowable Cost (MAC) ...
(Date:9/2/2014)... CALGARY, Alberta , September 2, 2014 ... der "State of the Art and Featured Research Session" ... Resverlogix Corp. (TSX: RVX) gab heute bekannt, dass Dr. Jan ... beim Kongress des europäischen Kardiologenverbandes (ESC) 2014 in ... In seinem Vortrag mit dem Titel " Effects of ...
(Date:9/2/2014)... CLARA, Calif. , Sept. 2, 2014   ... is now offering a special promotion for Invisalign. Invisalign ... of brackets and wires. It is often the orthodontic ... prefer the convenience and aesthetics of it. For a ... which is a significant savings from the usual cost. ...
Breaking Medicine Technology:Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 3RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 4RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 5RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 6Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2
... Inc. (Nasdaq: ENMD ), a clinical-stage pharmaceutical company ... Wei-Wu He, Ph.D has joined the Board of Directors as ... a member of the Board of Directors. (Logo: ... currently the CEO and Chairman of OriGene Technologies, Inc. He ...
...  United Therapeutics Corporation (NASDAQ: UTHR ) today ... on February 3, 2012 from Sandoz Inc. (Sandoz) advising ... (ANDA) to the U.S. Food and Drug Administration (FDA) ... 10 mg/mL strength of Remodulin® (treprostinil) injection.  ...
Cached Medicine Technology:Biotech Leaders Wei-Wu He, Ph.D and Tak W. Mak, Ph.D Join EntreMed's Board of Directors 2Biotech Leaders Wei-Wu He, Ph.D and Tak W. Mak, Ph.D Join EntreMed's Board of Directors 3Biotech Leaders Wei-Wu He, Ph.D and Tak W. Mak, Ph.D Join EntreMed's Board of Directors 4United Therapeutics Receives Paragraph IV Notice Letter for Remodulin 2
(Date:9/2/2014)... Friendship Village of Schaumburg is ... creates a contemporary marketing presence and visually solidifies ... organization, Friendship Senior Options,” said Stephen A. Yenchek, ... changing the logo, we are making sure that ... and their families.” , Friendship Village is a ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Cloud Medical ... of “Cloud Based” Medical Practice Business Operations solutions and ... of Digital Cyber Security solutions for all industries announced ... on the trading floor of the CME in Chicago ... DeLaGarza stated that we are very proud of the ...
(Date:9/2/2014)... NY (PRWEB) September 02, 2014 The ... new blood thinners is growing at a rapid pace, ... to mount in courts around the U.S., Bernstein Liebhard ... American Journal of Medicine, within a year of its ... prescribed Xarelto as warfarin, a blood thinner that has ...
(Date:9/2/2014)... SC (PRWEB) September 02, 2014 The Wm. ... outreach fair and public town hall meeting for Veterans and ... available at the outreach fair to provide Veterans with valuable ... McMurry. “The town hall will provide a forum where we ... VA programs.” , The outreach fair will be held 4:45 ...
(Date:9/2/2014)... 02, 2014 On August 30, 2014, ... titled “Why You Should Wash Your Face .” ... the global population breathes air considered polluted by the ... lodge in the skin’s pores destroying its natural oils. ... free radicals that may cause cell damage, redness, ...
Breaking Medicine News(10 mins):Health News:Friendship Village of Schaumburg In Illinois Announces New Logo 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 3Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 3Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 4Health News:Simon Ourian, Kim Kardashian’s Doctor: Air Pollution May Be Aging Your Skin 2
... common problem among women. However statistics show that among people ... with knee joint pain, obese people are in the majority. ... definite about the reasons for the knee pain. //Majority of ... briefly. ,The basic sturcture of knee joint is composed ...
... young as even 3 days old can tell whether someone ... author, doubts that humans have evolved to be sensitive to ... Farroni is a researcher with the Centre for Brain and ... University of London.// ,Farroni, felt that newborns are not ...
... The first major trans-Atlantic telesurgical operation has been carried ... from a patient in eastern France by remotely operating ... for a surgeon to perform an operation on a ... Institute of Telesurgery in Strasbourg say the procedure was ...
... their new study suggested that, along with calcium, protein ... Getting enough calcium is essential for building and maintaining ... men and women who were taking calcium citrate malate ... density increased most in people whose diets contained the ...
... a biomedical engineer at the University of Pittsburgh makes ... your eyes. The prototype device merges the visual outer ... scan of what lies beneath. It creates the effect ... 3D location with the patient, showing blood vessels, muscle ...
... with Alzheimer’s may worsen the symptoms of Parkinson’s ... could improve treatments for these conditions, say US ... up to one-third of Alzheimer’s patients develop Parkinson’s ... ,To research a possible link between ...
Cached Medicine News:Health News:New combined therapy for Knee Joint pain 2Health News:Newborns Know how to make eye contact 2Health News:Calcium and Protein Equals Strong Bones 2Health News:New form of ultrasonic vision 2
Allograft implants can be easily used to repair and promote the healing of a wide variety of bone and other tissue defects....
Allograft implants can be easily used to repair and promote the healing of a wide variety of bone and other tissue defects....
... Solo Lumbar Allografts are ... that maximizes compressive strength and ... permits the use of preferred ... healing. Specially designed instruments facilitate ...
... comprised of two cortical planks of ... cortical planks provide strength for anterior ... a lattice for remodeling, ensuring an ... surface teeth increase the stability of ...
Medicine Products: